Latest Content

Kromek Group

Increasingly more confident

Hot on the heels of winning up to $3.3m of home security contracts in late July with the US government, Kromek today said that it had secured two more significant orders. Both within healthcare and together worth >$1m.

 View

  • 20 Aug 18
  • -
  • -

Ergomed

Building for growth

Ergomed’s strategy is to become a global leader in pharmacovigilance and orphan drug development services by 2020. This refocusing of the business, communicated earlier in the year, moves Ergomed away from its reliance on the risk/reward profile of development deals and will ultimately result in a much better, more visible, and cash-generating story.

 View

  • 16 Aug 18
  • -
  • -

Realm Therapeutics

Review underway after Atopic Dermatitis miss

Realm Therapeutics plc (RLM), a clinical stage bio-pharmaceutical company focused on developing novel therapeutics in immune-related diseases based on its proprietary hypochlorous acid (HOCl) technology, has reported preliminary top-line data from its Phase II trial of PR022 in Atopic Dermatitis, in tandem with H1’18 financial results.

 View

  • 15 Aug 18
  • -
  • -

Destiny Pharma

Clinical progress with XF drug platform

Destiny Pharma (DEST) is developing a pipeline of novel antimicrobials from its XF drug platform, to help combat highly prevalent and virulent bacteria. These include eight so far tested of those classed as urgent threats by the World Health Organisation and Centers for Disease Control (CDC), including MRSA (methicillin-resistant Staphylococcus aureus). The unique mechanism of DEST’s new class of drug candidates could also help to overcome Anti-Microbial Resistance (AMR) that is a major limiting factor with standard antibiotic treatments.

 View

  • 13 Aug 18
  • -
  • -

Elektron Technology

Upgrading forecasts again

Disruptive technology is turning the world upside down. Look anywhere from online retailing, autonomous vehicles and social media, to big data, augmented reality and artificial intelligence. Life is changing, and fast. Similarly we think Elektron’s Checkit service is set to transform the workplace, simplifying everyday tasks such as cleaning schools, monitoring food safety and testing patient blood samples, whilst simultaneously delivering substantial time/cost savings, along with improving customer service and regulatory compliance.

 View

  • 09 Aug 18
  • -
  • -

Gattaca

Base camp reached and business stable

Like its namesake movie - where the central character overcomes testing conditions – we think Gattaca will also emerge much fitter after its recent lean spell. Encouragingly the company has made a good start, albeit there is still plenty of climbing ahead.

 View

  • 02 Aug 18
  • -
  • -
 

Equity Development Research and Daily Commentaries

Research Tree offers Equity Development research, providing ongoing coverage of 53 shares. We offer 313 reports from Equity Development on Research Tree.

  • Research reports provided by Equity Development

  • Companies covered by Equity Development

  • Sectors covered by Equity Development


Related Content

View the latest research on other companies in the sector. 

Fastforward Innovations

Firing on all cylinders

Being able to consistently deliver out-sized investment returns, is all about managing risk and finding high quality, growth stocks at the right price. We’ve seen this already in 2016 with many such smallcaps, like Keywords Studios, Fevertree Drinks, Boohoo, GW Pharmaceuticals and Tristel. Another stock we think that in due course could join this select band, is FastForward (up 100% since mid Oct’15) which invests exclusively in rapidly expanding technology firms. Today FFWD holds non-controlling positions in nine such privately owned businesses, which we understand are all either meeting or exceeding their internal plans. Here, progress was said to be “incredibly positive and very encouraging” yesterday, with updates being released in relation to three of them.

 View

  • 30 Nov 16
  • -
  • -